Moderna says Omicron-specific booster generates strong immune response

Tribune Web Desk

Updated At : 10:37 PM Jun 08, 2022 IST

Unlock Exclusive Insights with The Tribune Premium

Take your experience further with Premium access. Thought-provoking Opinions, Expert Analysis, In-depth Insights and other Member Only Benefits

Yearly Premium ₹999 ₹349/Year

Yearly Premium $49 $24.99/Year

June 8

Moderna Inc said on Wednesday its COVID-19 vaccine booster that targets both the original coronavirus strain and Omicron produced a better immune response against the variant than its original vaccine.

The booster raised virus-neutralising antibodies by eight-fold in a study. The vaccine was generally well-tolerated, with side effects comparable to a booster dose of mRNA-1273 at the 50 micrograms level.

“We are submitting our preliminary data and analysis to regulators with the hope that the Omicron-containing bivalent booster will be available in the late summer,” Chief Executive Stephane Bancel said in a statement.

Share of Moderna were up 2% in premarket trading.

The Tribune, now published from Chandigarh, started publication on February 2, 1881, in Lahore (now in Pakistan). It was started by Sardar Dyal Singh Majithia, a public-spirited philanthropist, and is run by a trust comprising five eminent persons as trustees.

The Tribune, the largest selling English daily in North India, publishes news and views without any bias or prejudice of any kind. Restraint and moderation, rather than agitational language and partisanship, are the hallmarks of the newspaper. It is an independent newspaper in the real sense of the term.

The Tribune has two sister publications, Punjabi Tribune (in Punjabi) and Dainik Tribune (in Hindi).

Remembering Sardar Dyal Singh Majithia

Designed and developed by : SORTD

Unlock Exclusive Insights with The Tribune Premium

Suggested Articles